Anke van den Berg
prof. dr.
I work as a clinical molecular biologist in the department of Pathology. In this function I supervise and implement advanced molecular diagnostic techniques. Within my research line, I focus on the molecular pathogenesis of B-cell Hodgkin and non-Hodgkin lymphoma. The specific fields of interest are genomic aberrations, genetic susceptibility, and the role of small and long noncoding RNAs. I have several international collaborations and am PI and co-PI in various projects.
Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non-Small Cell Lung Cancer
Published in: Clinical Cancer Research
Access to document
10.1158/1078-0432.CCR-16-1631
PURPOSE: ALK rearrangement detection using fluorescence in situ hybridization (FISH) is the standard test to identify non-small cell lung carcinoma (NSCLC) patients eligible for treatment with ALK inhibitors. Recently ALK protein expression in resectable NSCLC showed predictive value. We evaluated tumor response rate and survival after crizotinib treatment of advanced NSCLC patients with ALK activation using both dichotomous immunohistochemical staining (IHC) and FISH. Design Stage IV NSCLC patients treated with crizotinib were selected. Tumor response was assessed. ALK rearrangements were detected by FISH (Vysis ALK-Break-Apart FISH-Probe KIT) and...
A. J. van der Wekken, Rianne Pelgrim, Nils 't Hart, Naomi Werner, Mirjam Mastik, Lizza Hendriks, Erik Hfm van der Heijden, Monika Looijen-Salamon, A Joop de Langen, Jeske Staal-van den Brekel, Sietske Riemersma, Ben E van den Borne, Ernst-Jan M Speel, Anne-Marie C Dingemans, T Jeroen N Hiltermann, Anke van den Berg, Wim Timens, Ed Schuuring, H. J. M. Groen
Treatment decision-making of rare ERBB2 (HER2) mutations in lung cancer; a role for multidisciplinary molecular tumor boards: A role for multidisciplinary molecular tumor boards
Published in: Cancer Research
Access to document
10.1158/1538-7445.AM2017-754
Arja ter Elst, Nils A. 't Hart, Anthonie J. van der Wekken, Wim Timens, Lucie B. Hijmering-Kappelle, Geke A. Hospers, Hilde Jalving, Elise M. van der Logt, Leon C. van Kempen, Sjoukje F. Oosting, Matthew R. Groves, T. Jeroen Hiltermann, Anke van den Berg, Harry J. Groen, Ed Schuuring
A comprehensive RNA-based assay for treatment prediction in non-small cell lung cancer patients
Published in: Cancer Research
Access to document
10.1158/1538-7445.AM2017-2785
Klaas Kok, Jaicong Wei, Anna Rybczynska, Martijn Terpstra, Anthonie van der Wekken, Jeroen Hilterman, Ed Schuuring, Rolf Sijmons, Harry Groen, Anke van den Berg
Molecular Tumor Board treatment predictions on rare EGFR exon 20 mutations
Published in: Cancer Research
Access to document
10.1158/1538-7445.AM2017-2718
Copy number alterations assessed at the single-cell level revealed mono- and polyclonal seeding patterns of distant metastasis in a small cell lung cancer patient
Published in: Annals of Oncology
Access to document
10.1093/annonc/mdx182
P Ferronika, H. Bos, van den, A Taudt, D C J Spierings, A Saber, T J N Hiltermann, K. Kok, David Porubsky, A J van der Wekken, W Timens, F Foijer, M Colomé-Tatché, H J M Groen, P M Lansdorp, Anke Berg, van den